<PAGE> 1
EXHIBIT 11.1
ILEX ONCOLOGY, INC.
SEPTEMBER 30, 2000 - QUARTERLY REPORT ON FORM 10-Q
--------------------------------------------------------------------------------
COMPUTATION OF NET LOSS PER SHARE
(In Thousands, Except Per Share Amounts)(Unaudited)
<TABLE>
<CAPTION>
Three Months Ended Nine Months Ended
September 30, September 30,
-------------------- --------------------
2000 1999 2000 1999
-------- -------- -------- --------
<S> <C> <C> <C> <C>
COMPUTATION OF BASIC NET LOSS PER SHARE:
Net loss $ (8,556) $(16,196) $(16,484) $(43,285)
======== ======== ======== ========
Weighted average shares of common stock outstanding 24,914 16,168 23,929 13,928
======== ======== ======== ========
Basic net loss per share $ (0.34) $ (1.00) $ (0.69) $ (3.11)
======== ======== ======== ========
COMPUTATION OF DILUTED NET LOSS PER SHARE:
Net loss $ (8,556) $(16,196) $(16,484) $(43,285)
Preferred stock dividends not incurred upon assumed conversion of
preferred stock 75 7 225 7
-------- -------- -------- --------
Loss available to common stockholders assuming conversion of subsidiary's
preferred stock $ (8,481) $(16,189) $(16,259) $(43,278)
======== ======== ======== ========
Weighted average number of shares of common stock and common stock
equivalents outstanding-
Weighted average shares of common stock outstanding 24,914 16,168 23,929 13,928
Weighted average number of common stock equivalents applicable to
stock options, warrants and subsidiary's preferred stock 1,170 588 1,161 471
-------- -------- -------- --------
Common stock and common stock equivalents 26,084 16,756 25,090 14,399
======== ======== ======== ========
Diluted net loss per common stock and common stock equivalents(a) $ (0.33) $ (0.97) $ (0.65) $ (3.01)
======== ======== ======== ========
</TABLE>
(a) This calculation is submitted in accordance with Item 601(b)(11) of
Regulation S-K although it is not required by SFAS No. 128 because it is
antidilutive.